Quantifying treatment burden: the patient burden score a study of 758 patients across three clinical urologic scenarios
2024

Measuring Treatment Burden in Urology

Sample size: 758 publication Evidence: moderate

Author Information

Author(s): Gofrit Ofer N., Goldberg S. Nahum, Lorber Amitay, Duvdevani Mordechai, Wygoda Marc, Hidas Guy, Yutkin Vladimir, Pikarsky Liat Appelbaum

Primary Institution: Hadassah Hebrew University Hospital

Hypothesis

Can a comprehensive scale be developed to measure the burden of treatment in urology?

Conclusion

Percutaneous ablation, trimodal therapy, and ureteroscopy provide similar success rates to more invasive treatments but with significantly lower treatment burden scores.

Supporting Evidence

  • Both percutaneous ablation and partial nephrectomy had a 5-year recurrence-free survival rate of ≥97%.
  • Trimodal therapy and radical cystectomy showed identical 3-year disease-specific survival rates of 73%.
  • Ureteroscopy and shockwave lithotripsy achieved high stone-free rates of ≥97%.

Takeaway

This study created a way to measure how much different treatments can stress patients, helping them choose the best option.

Methodology

A panel of experts developed a burden score scale, which was retrospectively calculated for patients in three urologic scenarios.

Potential Biases

Selection bias due to non-random patient allocation.

Limitations

The study is retrospective, which may introduce selection bias, and the burden weights are not universally applicable.

Participant Demographics

Patients treated in a tertiary center for small renal masses, muscle-invasive bladder cancer, and upper ureteral stones.

Statistical Information

P-Value

<0.01

Statistical Significance

p<0.01

Digital Object Identifier (DOI)

10.1007/s00345-024-05378-3

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication